Halozyme Therapeutics, Inc. (HALO) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

75/ 100

GoAI Score

Buy

Valuation

99

Deep Value

Sentiment

70

Bullish

Risk

27

Moderate Risk

Momentum

55

Neutral

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Industry: Biotechnology
Sector: Healthcare
Headquarters: US

Market position

Day range

Current $110.42

$109.7$112.65

52-week range

Current $110.42

$61.23$116.85

Open: $109.7
Previous close: $109.84
Volume: 1.85M
Market cap: 13.1B USD
50-day average: $105.65; +4.52% above average
200-day average: $79.419; +39.03% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 10.07B USD
P/E (TTM): 31.37×
P/B (TTM): 90.21×
P/S (TTM): 7.87×
EV / EBITDA: 17.58×
Earnings yield: 3.93%
Free cash flow yield: 7.99%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 82.42%
Operating margin: 55.95%
Net margin: 24.86%
Return on equity: 649.18%
Return on assets: 12.55%
Return on invested capital: 23.20%

Financial health

Debt / equity: 14.95×
Current ratio: 4.66×
Altman Z-score: 5
Piotroski F-score: 6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

1.4B USD+37.55%

Operating income

802.59M USD+45.54%

Net income

316.89M USD-28.64%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	1.4B USD	1.02B USD	829.25M USD	660.12M USD	443.31M USD
Cost of goods sold	228.77M USD	159.42M USD	192.36M USD	139.3M USD	81.41M USD
Gross profit	1.17B USD	855.91M USD	636.89M USD	520.81M USD	361.9M USD
Research and development	81.49M USD	79.05M USD	76.36M USD	66.61M USD	35.67M USD
Selling, general, and administrative	207.09M USD	154.34M USD	149.18M USD	143.53M USD	50.32M USD
Operating expenses	365.24M USD	304.43M USD	299.32M USD	253.28M USD	86M USD
Interest expense	18.13M USD	18.1M USD	18.76M USD	16.95M USD	7.53M USD
Depreciation and amortization	88.05M USD	81.31M USD	84.86M USD	49.64M USD	3M USD
Operating income	802.59M USD	551.48M USD	337.57M USD	267.53M USD	275.9M USD
Net income	316.89M USD	444.09M USD	281.59M USD	202.13M USD	402.71M USD

Company facts updated Oct 12, 2026.

Earnings

EPS beat rate: 82%; 9 beats, 2 misses, 0 met estimates
Average EPS surprise: +3.24%; 11 comparable reports
Latest EPS result: 2.28; Estimate 1.79 · Beat by 27.37%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Latest fiscal-year EPS: 2.56; FY2025 · -25.36% year over year
Latest fiscal-year revenue: 1.4B USD; FY2025 · +37.55% year over year
Next fiscal-year EPS consensus: 8.53; FY2026 · 4 analysts
Next fiscal-year revenue consensus: 1.85B USD; FY2026 · 6 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$106

4.00% downside

Past 12 months12-month forecastHigh $130Average $106Low $90.00

Rating distribution

27 ratings

Strong buy00%

Buy1867%

Hold830%

Sell14%

Strong sell00%

Recent analyst actions

11 institutions

HALO news

defenseworld.netOct 11, 2026

Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,191,600.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $109.58, for…

Read source

defenseworld.netOct 11, 2026

Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,188,000.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the business's stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $109.40,…

Read source

zacks.comOct 8, 2026

HALO Wins Court Order Blocking Merck's Keytruda SC in Europe

Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.

Read source

zacks.comOct 7, 2026

HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX

Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.

Read source

prnewswire.comOct 7, 2026

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets

SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be infringing one…

Read source

prnewswire.comOct 6, 2026

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

Expanded agreement increases argenx's exclusive access to ENHANZE® from six to eight targets SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today…

Read source